| 摘要 |
The present invention uses Paclitaxel and/or Colchicine in an appropriate carrier to inhibit wound contraction. Paclitaxel is an antimicrotubule agent that is currently used as a cancer chemotherapeutic drug. Colchicine inhibits microtubule dependent processes such as cell contraction and motility. It has been given orally for decades to treat gout. Previous studies using Colchicine to control wound contraction have been unsuccessful because of both local and systemic toxicity. Studies using the present invention demonstrate that Paclitaxel and Colchicine, when applied to wounds locally (either topically or by injection) in concentrations which are much lower than those previously studied, inhibit wound contraction, collagen deposition and granulation tissue growth. When combined with D-penicillamine, a drug that inhibits collagen cross-linking, the combination inhibits wound contraction, granulation tissue growth (nascent tissue that forms in the wound immediately post-injury), and intramuscular collagen deposition; epithelialization (sealing of the wound) is promoted.
|
